52 Week Range
As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Livzon Pharma Expects Net Profit To Rise Up To 10% Y/Y In 2021
Livzon Pharmaceutical Made A Total Repurchase Of 2.7 Million H Shares Of Co As At 6 Dec
Livzon Pharma's Covid-19 Vaccine Candidate Gets Approval To Conduct Phase III Clinical Trial In Pakistan
LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.
Biotechnology & Drugs
No.132, Guihua Road North, Gongbei
Chairman of the Board, Non-Executive Director
President, Executive Director
Vice Chairman of the Board, Vice President, Executive Director
Vice Chairman of the Board, Non-Executive Director
Finance Director, Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
A potential COVID-19 vaccine developed by a biotech firm affiliated with China's Livzon Pharmaceutical Group Inc (Livzon) has entered a late-stage trial, Livzon said late on Thursday.
A potential COVID-19 vaccine developed by a biotech firm affiliated with China's Livzon Pharmaceutical Group Inc (Livzon) has entered a late-stage trial, Livzon said in a filing late on Thursday.
A potential COVID-19 vaccine developed by a subsidiary of China's Livzon Pharmaceutical Group Inc appeared safe and able to elicit antibodies in healthy adults in a mid-stage clinical trial, Chinese researchers said.
China's medical products regulator has approved clinical trials for a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc, the Chinese company said late on Tuesday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.